Health Affairs, 28, no. 5 (2009): w770-w781 (Published online 21 July 2009) doi: 10.1377/hlthaff.28.5.w770 © 2009 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Figures Only Full Text (HTML) Reprint (PDF) Appendices TOC Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Google Scholar Articles by Crystal, S. Articles by Gerhard, T. PubMed PubMed Citation Articles by Crystal, S. Articles by Gerhard, T. Related Collections Insurance Coverage Legal/Regulatory Issues Managed Care - Mental Health Mental Health/Substance Abuse Research And Technology Health Spending Consumer Issues Evidence-Based Medicine Related Articles

Web Exclusives

Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges

Atypical antipsychotic medications are increasingly used for a wide range of clinical indications in diverse populations, including privately and publicly insured youth and elderly nursing home residents. These trends heighten policy challenges for payers, patients, and clinicians related to appropriate prescribing and management, patient safety, and clinical effectiveness. For clinicians and patients, balancing risks and benefits is challenging, given the paucity of effective alternative treatments. For health care systems, regulators, and policymakers, challenges include developing the evidence base on comparative risks and benefits; defining measures of treatment quality; and implementing policies that encourage evidence-based practices while avoiding unduly burdensome restrictions.

                      What's this?

Related Articles

• Robert A. Rosenheck and Michael J. Sernyak
  Developing A Policy For Second-Generation Antipsychotic Drugs
  Health Affairs, September/October 2009; 28(5): w782-w793.
  [Abstract] [Full Text] [PDF]
   
  
• David O. Meltzer, Anirban Basu, and Herbert Y. Meltzer
  Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?
  Health Affairs, September/October 2009; 28(5): w794-w808.
  [Abstract] [Full Text] [Figures Only] [PDF] [Technical Appendices]
   
  
• David O. Meltzer, Anirban Basu, and Herbert Y. Meltzer
  Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?
  Health Affairs, September/October 2009; 28(5): w794-w808.
  [Abstract] [Full Text] [Figures Only] [PDF] [Technical Appendices]